Fellowship · Omaha, NE
Sponsored by University of Nebraska Medical Center College of Medicine
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
Leukemia · 2022 · 3,530 citations · Joseph Khoury
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
Leukemia · 2022 · 3,300 citations · Joseph Khoury
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Nature medicine · 2024 · 238 citations · Gabriel Caponetti
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
The New England journal of medicine · 2024 · 205 citations · Anamarija Perry
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
The Lancet. Haematology · 2023 · 226 citations · Joseph Khoury
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
The Lancet. Haematology · 2023 · 116 citations · Joseph Khoury
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 31 citations · Anamarija Perry
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Blood cancer journal · 2022 · 112 citations · Joseph Khoury